Form 8-K - Current report:
SEC Accession No. 0001628280-25-021514
Filing Date
2025-05-01
Accepted
2025-05-01 16:03:36
Documents
16
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20250501.htm   iXBRL 8-K 25507
2 EX-99.1 ardx-20250331xexhibit991.htm EX-99.1 92440
6 ardx-20250501_g1.jpg GRAPHIC 75659
7 picture1a.jpg GRAPHIC 19078
  Complete submission text file 0001628280-25-021514.txt   463395

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20250501.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20250501_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20250501_pre.xml EX-101.PRE 13046
18 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20250501_htm.xml XML 2795
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 25902918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)